Add BrightSurf on Google Email

Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

A landmark EORTC trial with over 20 years of follow-up found that irradiation of internal mammary and medial supraclavicular lymph nodes reduces breast cancer mortality, but does not improve overall survival. Long-term cardiac and pulmonary toxicity was reported more frequently after IM-MS irradiation.

SourceEuropean Organisation for Research and Treatment of Cancer·JournalCA A Cancer Journal for Clinicians·TypeNews article·DateMay 17, 2026

Screening modestly reduces prostate cancer deaths

Screening with a PSA blood test reduces prostate cancer deaths by approximately 2 for every 1,000 men screened. The review found that 500 men would need to be invited to screening to prevent one prostate cancer death.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateMay 14, 2026

Preclinical efficacy of experimental peptide therapy suggests a new target for metastatic breast cancer treatments, UTHealth Houston researchers find

Researchers at UTHealth Houston have discovered a new target for metastatic breast cancer treatments using experimental peptide therapy. The study found that the peptide BLMP6 targets fibulin-4, a protein expressed in high levels in metastatic breast cancers.

SourceUniversity of Texas Health Science Center at Houston·JournalMolecular Therapy Oncology·DateApr 29, 2026

New awards and publications showcase achievements from staff at the National Comprehensive Cancer Network

NCCN staff received awards and publications for advancing quality cancer care, including Dr. Alyssa Schatz's Leadership in Policy, Equity, and Advocacy award and Faviolla Baez-Cruz's publication on biochemical research. The National Comprehensive Cancer Network is recognized for its work to improve outcomes for people with cancer.

AI tool that estimates biological age from face photos could serve as prognostic biomarker for cancer

A new study suggests that an AI tool analyzing facial changes can serve as a prognostic biomarker for cancer prognosis. The researchers found that patients with higher biological aging rates had lower chances of survival, and the effect was strongest when photos were taken over longer intervals.

SourceMass General Brigham·JournalNature Communications·TypeComputational simulation/modeling·DateApr 28, 2026

26 Years of development of EGFR-TKIs for non-small cell lung cancer: Clinical application and resistance research progress

EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 28, 2026

New targeted therapy shows promise against aggressive childhood and adult cancers

A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.

SourceUniversity of British Columbia·JournalCancer Discovery·TypeExperimental study·DateApr 23, 2026

Deceptive ovarian cancer case mimics pelvic abscess, delaying diagnosis in postmenopausal woman

A rare case of mucinous ovarian carcinoma was reported in a postmenopausal woman, initially misdiagnosed as a pelvic abscess due to nonspecific symptoms and radiologic features. The diagnosis was confirmed after advanced imaging and tumor marker assessment. Early recognition is crucial for timely diagnosis and effective treatment of th...

SourceImpact Journals LLC·JournalOncoscience·TypeCase study·DateApr 22, 2026

Dual-pathway blockade therapy offers hope for rare, hard-to-treat gynecological clear cell cancers

Researchers have found that combining pembrolizumab and lenvatinib shows promise in treating recurrent clear cell ovarian and endometrial cancers with poor responses to standard treatments. The LARA trial provides encouraging responses for patients with this rare and difficult-to-treat cancer subtype.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalThe Lancet Oncology·TypeExperimental study·DateApr 22, 2026

Primary breast tumors already harbor cells with metastatic potential

Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.

SourceUniversidad Miguel Hernandez de Elche·JournalNature Communications·TypeExperimental study·DateApr 20, 2026

Alliance study shows new promise against locally advanced lung cancer

A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...

SourceAlliance for Clinical Trials in Oncology·JournalLung Cancer·TypeExperimental study·DateApr 20, 2026

Young-onset colorectal cancer mortality by education

A nationwide study reveals that individuals with lower educational attainment are more likely to die from colorectal cancer at a younger age. The disparity in young-onset CRC mortality nearly doubled over the past three decades among those with 12 years or less education compared to those with 16 or more years of education.

SourceJAMA Network·JournalJAMA Oncology·DateApr 16, 2026

3D tumor organoids give brain tumor researchers new scientific opportunities

Researchers at St. Jude Children's Research Hospital developed patient-derived tumor organoids that accurately reflect the biologic underpinnings of embryonal brain tumors. The models enable faster functional assays and preclinical drug testing without relying on newly obtained tumor samples, advancing the study of pediatric brain tumors.

SourceSt. Jude Children's Research Hospital·JournalScience Advances·DateApr 15, 2026

Survivors of adolescent, young adult cancers at double the risk of future cancers

Research from Alberta reveals that survivors of adolescent and young adult cancers are at double the risk of developing most types of later cancers. Lymphoma and breast cancer were found to be the most common subsequent cancers after an initial diagnosis, with breast, colorectal, and lung cancers making up 43% of cases.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateApr 13, 2026

Development and successful treatment of spinal mixed histiocytosis in an elderly woman following two relapses of BRAF-mutated unifocal skull langerhans cell histiocytosis

A 76-year-old woman developed spinal mixed histiocytosis after multiple relapses of BRAF-mutated unifocal skull Langerhans cell histiocytosis. She was treated successfully with targeted therapy, highlighting the importance of routine PET/CT screening and genetic testing for refractory cases.

SourceXia & He Publishing Inc.·JournalOncology Advances·DateApr 13, 2026

Establishment of a method for amplifying the full genome of human papillomavirus 16 using overlapping extension polymerase chain reaction

This study established a novel method for amplifying the entire HPV16 genome, demonstrating high sensitivity and specificity. The overlapping extension polymerase chain reaction (PCR) approach enabled effective amplification of samples as low as 2 copies/μL, with stable results at higher concentrations.

SourceXia & He Publishing Inc.·JournalOncology Advances·DateApr 10, 2026

Practice-defining NRG Oncology trial finds chemotherapy followed by letrozole is the standard for advanced, low grade serous gynecologic carcinoma

The phase III NRG GY019 trial found that paclitaxel/carboplatin followed by letrozole is the standard treatment for patients with stage II-IV low-grade serous ovarian carcinoma. The study also showed that letrozole monotherapy did not demonstrate non-inferiority to the combination, but was associated with fewer serious side effects.

AACR: Targeted drug delivery for colorectal cancer, COVID-19’s impact on breast cancer outcomes, AI in cancer diagnosis and more

UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.

Researchers find way to treat lung cancer and associated muscle wasting at the same time

A new study from Oregon State University has found a way to treat both lung cancer and associated muscle-wasting cachexia using lipid nanoparticles. The treatment involves loading the nanoparticles with follistatin messenger RNA, which triggers cells to produce the protein, promoting muscle tissue growth while inhibiting tumors.

SourceOregon State University·JournalJournal of Controlled Release·TypeExperimental study·DateApr 6, 2026